GAOMA Therapeutics is pleased to announce that Bpifrance allocated a €90k grant to the company. This funding will be dedicated to the exploration of the potential efficacy of GAOMA’s drug candidate GAO-3-02 in Alzheimer’s Disease preclinical models.
